Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

(2013) M Stotz et al.   BRITISH JOURNAL OF CANCER

Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients

(2013) M Pichler et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

(2013) Hideki Ueno et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials

(2012) Domenico Ciliberto et al.   EUROPEAN JOURNAL OF CANCER

Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer

(2012) De-shen Wang et al.   MEDICAL ONCOLOGY

Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients

(2011) Basem Azab et al.   ANNALS OF SURGICAL ONCOLOGY

Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer

(2011) W Chua et al.   BRITISH JOURNAL OF CANCER

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

(2011) M J Proctor et al.   BRITISH JOURNAL OF CANCER

Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer

(2011) Mi Ran Jung et al.   JOURNAL OF SURGICAL ONCOLOGY

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) is Associated with Reduced Disease-free Survival Following Curative Resection of Pancreatic Adenocarcinoma

(2011) G. Garcea et al.   WORLD JOURNAL OF SURGERY

Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio

(2010) Imran Bhatti et al.   AMERICAN JOURNAL OF SURGERY

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

(2010) Xin An et al.   BIOMARKERS

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model

(2010) Jadwiga Jablonska et al.   JOURNAL OF CLINICAL INVESTIGATION

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer

(2010) Michael Haas et al.   TUMOR BIOLOGY

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

(2009) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma

(2008) Richard A. Smith et al.   AMERICAN JOURNAL OF SURGERY

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma

(2008) Dhanwant Gomez et al.   JOURNAL OF SURGICAL ONCOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE